Figure 1. Topo II inhibitor addition increases mitotic SUMOylation on mitotic chromosomes in XEEs. (A) Schematic representation for preparation of mitotic replicated chromosomes treated with inhibitors from XEEs (see Materials and methods). (B) Inhibitor-treated mitotic chromosomes were isolated from XEEs as shown in A with (+dnUbc9) and without (control) dnUbc9 and subjected to Western blotting. Histone H4 was probed as a loading control for the mitotic chromosomes. (C–E) Quantification of mitotic SUMOylation in the inhibitor-treated mitotic chromosomes relative to DMSO-treated chromosomes, percentage SUMOylation of Topo IIα and PARP1 as seen in B, from four independent experiments (n = 4). Error bars, standard deviation. *, P value from Student’s t test. **, Statistically significant difference, P ≤ 0.01.
Figure 1.

Topo II inhibitor addition increases mitotic SUMOylation on mitotic chromosomes in XEEs. (A) Schematic representation for preparation of mitotic replicated chromosomes treated with inhibitors from XEEs (see Materials and methods). (B) Inhibitor-treated mitotic chromosomes were isolated from XEEs as shown in A with (+dnUbc9) and without (control) dnUbc9 and subjected to Western blotting. Histone H4 was probed as a loading control for the mitotic chromosomes. (C–E) Quantification of mitotic SUMOylation in the inhibitor-treated mitotic chromosomes relative to DMSO-treated chromosomes, percentage SUMOylation of Topo IIα and PARP1 as seen in B, from four independent experiments (n = 4). Error bars, standard deviation. *, P value from Student’s t test. **, Statistically significant difference, P ≤ 0.01.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal